Advanced Hematologic Malignancies
Showing 1 - 25 of >10,000
Hematologic Malignancy Trial in Boston (Home Transfusion Program Components)
Not yet recruiting
- Hematologic Malignancy
- Home Transfusion Program Components
-
Boston, MassachusettsDana-Farber Cancer Institute
Aug 18, 2022
Advanced Systemic Mastocytosis Trial (BLU-263, Azacitidine)
Not yet recruiting
- Advanced Systemic Mastocytosis
- (no location specified)
Nov 2, 2022
Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia Trial in Stanford
Recruiting
- Allogeneic Hematopoietic Cell Transplantation (HCT)
- +5 more
- Purified regulatory T-cells (Treg) plus CD34+ HSPC
- +7 more
-
Stanford, CaliforniaStanford University
Oct 28, 2021
Non-Hodgkin Lymphoma, Multiple Myeloma Trial in China (Maplirpacept)
Not yet recruiting
- Non-Hodgkin Lymphoma
- Multiple Myeloma
-
Beijing, Beijing, China
- +3 more
May 31, 2023
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia Trial in Tampa (Fludarabine, Cyclophosphamide,
Recruiting
- Chronic Lymphocytic Leukemia
- +4 more
- Fludarabine
- +2 more
-
Tampa, FloridaMoffitt Cancer Center
Jan 12, 2023
Relapsed/Refractory Acute Myeloid Leukemia (AML) Trial in Tianjin (NTQ2494 tablet)
Recruiting
- Relapsed/Refractory Acute Myeloid Leukemia (AML)
- NTQ2494 tablet
-
Tianjin, Tianjin, ChinaHematology Hospital of the Chinese Academy of Medical Sciences
Sep 17, 2023
Cancer, Solid Tumor, Hematologic Malignancy Trial in Hangzhou (engineered red blood cell WTX212)
Recruiting
- Cancer
- +2 more
- engineered red blood cell WTX212
-
Hangzhou, Zhejiang, ChinaZhejiang Provincial People'S Hospital
Jan 21, 2023
Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies Trial
Recruiting
- Relapsed or Refractory Acute Myeloid Leukemia (AML)
- +3 more
-
Birmingham, Alabama
- +26 more
Sep 12, 2022
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia Trial in United States (Orca-T,
Recruiting
- Acute Myeloid Leukemia
- +7 more
- Orca-T
- Standard-of-Care
-
Duarte, California
- +13 more
Jan 25, 2023
Hematologic Malignancies Trial in United States (IPI-145 (duvelisib))
Terminated
- Hematologic Malignancies
- IPI-145 (duvelisib)
-
New York, New York
- +3 more
Mar 15, 2021
Acute Myeloid Leukemia, Lymphoblastic Leukemia, Acute Leukemia Trial in Chicago (IM-TMI (3Gy), IM-TMI (6Gy), IM-TMI (9Gy))
Completed
- Acute Myeloid Leukemia
- +4 more
- IM-TMI (3Gy)
- +3 more
-
Chicago, IllinoisUniversity of Illinois at Chicago
May 18, 2021
Non-Hodgkin's Lymphoma (Disorder), Acute Lymphoid Leukemia, Disease (Disorder) Trial in Louisville, Houston (1A46 Injection)
Recruiting
- Non-Hodgkin's Lymphoma (Disorder)
- Acute Lymphoid Leukemia, Disease (Disorder)
- 1A46 Injection
-
Louisville, Kentucky
- +1 more
Aug 1, 2022
Advanced Solid Tumors, Hematological Malignancies Trial (ATG-018)
Not yet recruiting
- Advanced Solid Tumors
- Hematological Malignancies
- (no location specified)
Apr 14, 2022
Advanced Hematologic Malignancies, Advanced Solid Tumors Trial in Harbin, Changchun, Beijing (WJ01024)
Recruiting
- Advanced Hematologic Malignancies
- Advanced Solid Tumors
-
Harbin, Heilongjiang, China
- +2 more
Nov 3, 2021
Blood Cancer Trial (KCAT19 T cells)
Not yet recruiting
- Blood Cancer
- KCAT19 T cells
- (no location specified)
May 20, 2022
Solid Tumor, Hematological Malignancy Trial in Australia (ATG-017)
Recruiting
- Solid Tumor
- Hematological Malignancy
-
East Melbourne, Victoria, Australia
- +4 more
Jan 11, 2023
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin Trial in Worldwide (LOXO-338,
Active, not recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- +6 more
-
Duarte, California
- +8 more
Jan 11, 2023